announcements, page-9

sirtex more positive news today Treating Cancer with Microsphere Theraphy
By Tisha Powell
(06/22/06 - RALEIGH) - More than 200,000 women are diagnosed with invasive breast cancer
every year and up to 40% of those cases metastize to the liver. But now there's hope with
microsphere therapy.
Karen Aldrich is getting prepared for the Susan G. Komen Breast Cancer Foundation's Race for The
Cure. Karen is a breast cancer survivor. "They didn't think it was cancer, but when they did the
biopsy it came back positive."
Karen's cancer had already spread to her liver and after seven months of chemotherapy, she went
into remission and back to graduate school. "A week after graduation... I went back for a catscan
and found out the cancer had come back again... back in my liver."
Karen's tumor can't be surgically removed and her medication has stopped working. She's now
running out of options and hoping microsphere therapy will save her life.
A doctor has implanted millions of tiny radioactive microspheres into Karen's tumor.
Dr. Andrew Kennedy with Wake Radiology explains. "They are just large enough not to escape the
tumors, so they're implanted into the tumors and then over a two week period they give up all
their radiation."
Hopefully destroying the tumors. Kennedy adds. "We have seen very encouraging results from
breast cancer patients who chemotherapy in not shrinking the tumors in the liver and with the
application of this type of radiation we've got much better control of the tumors in the liver."
Karen remains positive that's what will happen for her. "I believe that I'm gonna beat this, and so
no matter what I'm gonna keep on trying. Whatever they got I keep trying it."
Sirtex Microspheres are FDA approved for the treatment of metastatic colorectal cancer, but
doctors are using the treatment for many other cancers and are seeing success.
Page 1 of 1 abc11tv.com: Treating Cancer with Microsphere Theraphy
6/9/2006 http://abclocal.go.com/wtvd/story?section=eye_on_health&id=4251385&ft=print

It looks like this market is not even factored into earnings models and this market indication alone is as large as the colorectal to liver indication. The sp is way behind the 8 positive developments and is the mostundervalued in the companys history relative to its ac complishments and high growth rate. Buyers here will get a double in very short term. Then as earnings and inlicencing deal to Genentech sp over $6. Buying on bid AS LONG AS IT LASTS FROM ILLITERATE NEWBIES HOWEVER i BELIEVE NOT MUCH SHARES ON OFFER EITHER TO BUY HERE TONITE, AS asx WILL BE GETTING MORE REPORTS FROM srx SOON